There is no single test for Alzheimer’s disease. Diagnosis involves a combination of cognitive screening, brain imaging, blood or spinal fluid analysis, and ruling out other conditions that can mimic dementia. The process typically starts with a brief memory test in a doctor’s office and can expand to more advanced tools depending on the results.
Modern diagnostic guidelines define Alzheimer’s as a biological disease, not just a set of symptoms. That means the goal of testing isn’t only to document memory loss. It’s to find the specific brain changes, particularly the buildup of two proteins called amyloid and tau, that define the disease. Here’s what each step looks like.
Cognitive Screening Tests
The first step is usually a short, structured test that measures how well your brain handles everyday thinking tasks. The two most common are the Mini-Mental State Exam (MMSE) and the Montreal Cognitive Assessment (MoCA). Both are scored out of 30 points and take about 5 to 10 minutes.
On the MMSE, a score of 24 or above is generally considered normal. The test covers orientation (knowing the date and where you are), attention, recall, language, and the ability to copy a simple drawing. The MoCA is slightly more demanding, testing eight cognitive areas including executive function, abstract reasoning, and delayed recall. A score of 26 or above is typically considered normal, with one extra point added if you have fewer than 12 years of formal education.
These screening tools are good at flagging problems, but they don’t diagnose Alzheimer’s on their own. A low score tells a doctor that something is affecting your thinking, not what’s causing it. If your results suggest impairment, the next step is usually more detailed testing and imaging.
Full Neuropsychological Evaluation
When screening raises concerns, you may be referred for a comprehensive neuropsychological evaluation. This is a longer battery of tests, often lasting several hours, that maps your strengths and weaknesses across memory, language, problem-solving, attention, and processing speed. The pattern of results helps distinguish Alzheimer’s from other types of dementia. For example, Alzheimer’s tends to hit new memory formation early, while other dementias may first affect attention or language.
Blood Tests to Rule Out Other Causes
Before pursuing an Alzheimer’s diagnosis, your doctor will want to make sure something treatable isn’t behind your symptoms. Routine blood work checks for thyroid disorders and low vitamin levels (particularly B12), both of which can cause memory problems and confusion that look a lot like early dementia. Infections, medication side effects, and depression can also mimic cognitive decline. These are straightforward to test for and important to catch because the memory problems they cause are often reversible.
Blood Tests for Alzheimer’s Proteins
A newer generation of blood tests can now detect Alzheimer’s-related proteins directly. The most promising measures a form of the tau protein called p-tau 217. A large meta-analysis found that plasma p-tau 217 detects amyloid buildup in the brain with 82% sensitivity and 86% specificity, and tau buildup with 83% sensitivity and 83% specificity. In practical terms, that means the test correctly identifies most people who have Alzheimer’s pathology and correctly clears most people who don’t.
These blood tests perform better in people who already have noticeable cognitive symptoms than in those who are still symptom-free. They’re increasingly used in clinical settings as a first-line biomarker test because they’re far less invasive than a spinal tap or a PET scan. A positive result may still need confirmation with imaging, but a negative result can help avoid unnecessary procedures.
Brain Imaging With MRI
An MRI scan doesn’t detect amyloid or tau directly, but it reveals structural changes in the brain that support a diagnosis. The primary target is the hippocampus, the brain’s memory hub. In Alzheimer’s, the hippocampus is already considerably damaged by the time symptoms first appear, and MRI can measure the degree of shrinkage.
Tracking hippocampal volume over time is one of the most useful MRI-based markers. People with mild cognitive impairment who carry the APOE4 gene (a major genetic risk factor) tend to show greater shrinkage in the hippocampus and surrounding temporal lobe compared to non-carriers. MRI also helps rule out other causes of cognitive decline, such as strokes, tumors, or fluid buildup in the brain.
PET Scans for Amyloid and Tau
PET imaging is the most direct way to see whether Alzheimer’s proteins have accumulated in a living person’s brain. Two types of PET scans are used, each targeting a different protein.
Amyloid PET scans use radioactive tracers that bind to amyloid plaques. A negative amyloid PET scan is particularly powerful: in one study, 100% of patients initially diagnosed with Alzheimer’s had their diagnosis changed to a non-Alzheimer’s condition after amyloid PET came back negative. That makes it one of the best tools for ruling the disease out.
Tau PET scans, using a tracer called flortaucipir (the first FDA-approved tau tracer), map the density and distribution of tau tangles across different brain regions. The pattern of tau spread corresponds to disease stage and correlates more closely with symptom severity than amyloid does. A negative tau PET also changes diagnoses, though slightly less decisively: about 76% of patients initially thought to have Alzheimer’s were reclassified after a negative tau scan.
Both scans are used in early-stage detection as well. In people with mild cognitive impairment, amyloid and tau PET can identify Alzheimer’s pathology before dementia fully develops, which helps with planning and may open the door to early treatment.
Spinal Fluid Analysis
A lumbar puncture (spinal tap) collects cerebrospinal fluid, which bathes the brain and carries traces of the proteins involved in Alzheimer’s. The key measurement is the ratio of two forms of amyloid protein. When this ratio drops below a specific threshold (roughly 0.10 for the amyloid-beta 42/40 ratio), it indicates that amyloid is being trapped in brain plaques instead of flowing freely in the fluid.
Spinal fluid testing has been a gold standard biomarker for years and remains highly accurate. The procedure involves a needle inserted into the lower back, which sounds intimidating but is routine and typically takes about 20 minutes. Discomfort is usually mild, and the most common side effect is a headache that resolves within a day or two. As blood-based tests improve, spinal fluid analysis is increasingly reserved for cases where blood results are unclear or additional confirmation is needed.
The Neurological Exam
Your doctor will also perform a hands-on neurological exam, checking reflexes, muscle strength, coordination, eye movements, and how you walk. In Alzheimer’s, common findings include asymmetrically brisk reflexes, reduced arm swing while walking, subtle tremor, increased muscle tone, and abnormal eye tracking movements. These signs tend to appear as the disease progresses and can help distinguish Alzheimer’s from other neurological conditions.
Genetic Testing
Genetic testing plays a limited but specific role. The strongest known genetic risk factor for late-onset Alzheimer’s in people of European descent is the APOE4 variant. Carrying one copy increases your risk. Carrying two copies (being homozygous) raises the chance of developing Alzheimer’s dementia to roughly 60% by age 85, with a more predictable age of onset than in non-carriers.
Rare mutations in three other genes cause early-onset Alzheimer’s, which typically appears before age 65. In those cases, nearly everyone who inherits the mutation develops the disease, and genetic testing can provide a definitive answer. For the more common late-onset form, APOE4 testing tells you about risk, not certainty. Many people with two copies never develop dementia, and many people with no copies do. Genetic testing is most useful for research settings and for guiding conversations about personal risk rather than confirming a diagnosis.
How the Pieces Fit Together
Alzheimer’s diagnosis is now understood as a biological continuum with three recognized stages: a preclinical phase where brain changes are present but symptoms haven’t appeared, mild cognitive impairment where memory problems are noticeable but daily life is still manageable, and dementia where cognitive decline significantly interferes with independence. Testing can identify the disease at any of these stages, though the combination of tools used depends on how far along someone is.
For most people, the diagnostic process starts with a cognitive screen and blood work in a primary care office. If those results raise concerns, the path typically moves to brain imaging and possibly biomarker testing through blood, spinal fluid, or PET scans. No single test is definitive on its own. The diagnosis comes from the pattern across multiple types of evidence, matching cognitive symptoms with biological proof that amyloid and tau are present in the brain.